Tanespimycin (17-AAG)

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

Molecular Weight(MW): 585.69

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Cited by 41 Publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Oxid Med Cell Longev, 2019, 2019:2050183

PubMed: 31178953 ( click the link to review the publication )

Int J Biol Sci, 2019, 15(2):312-324

PubMed: 30745823 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 371:63-73

PubMed: 30953615 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):102

PubMed: 30678647 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):737

PubMed: 31570706 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 47(6):2199-2215

PubMed: 29975948 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(5):1051-1060

PubMed: 29440291 ( click the link to review the publication )

Mycoses, 2018, 61(11):853-856

PubMed: 29998564 ( click the link to review the publication )

F1000Res, 2018, 7:1906

PubMed: 30881689 ( click the link to review the publication )

ACS Photonics, 2017, 5(2):487-494

PubMed: 29805987 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(5):409-423

PubMed: 28052321 ( click the link to review the publication )

Cell Mol Life Sci, 2017, 74(3):543-554

PubMed: 27592300 ( click the link to review the publication )

Am J Transl Res, 2017, 9(11):4945-4953

PubMed: 29218092 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:2219-2226

PubMed: 28458565 ( click the link to review the publication )

Cell, 2017, 170(5):845-859

PubMed: 28823557 ( click the link to review the publication )

Cancer Res, 2016, 76(4):965-73

PubMed: 26676744 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Medicinal Chemistry Research, 2016, 10.1007/s00044-016-1553-7

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 51: S659-S660

PubMed: ( click the link to review the publication )
Mol Cancer, 2014, 15:30

PubMed: 24927996 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(10):2237-41

PubMed: 25140805 ( click the link to review the publication )

Exp Gerontol, 2014, 52:55-69

PubMed: 24486130 ( click the link to review the publication )

Insect Mol Biol, 2014, 23(6):720-32

PubMed: 25060629 ( click the link to review the publication )

Julius Maximilians Universit, 2014, Kumari G

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(12):4269-82

PubMed: 24962213 ( click the link to review the publication )

Mol Cell, 2013, 50(3):368-78

PubMed: 23583076 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1830(11):5184-92

PubMed: 23850472 ( click the link to review the publication )

Mol Cell Biol, 2013, 33(12):2375-87

PubMed: 23572559 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2013, 10.1165/rcmb.2013-0214OC

PubMed: 24303801 ( click the link to review the publication )

J Exp Med, 2012, 209(2):259-73

PubMed: 22271575 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1823(4):911-9

PubMed: 22306003 ( click the link to review the publication )

J Biol Chem, 2012, 287(53):44109-20

PubMed: 23144451 ( click the link to review the publication )

Eukaryot Cell, 2012, 11(11):1324-32

PubMed: 22822234 ( click the link to review the publication )

Age (Dordr), 2012, 35(3):549-62

PubMed: 22252435 ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(18):7535-40

PubMed: 21502504 ( click the link to review the publication )

J Nat Prod, 2011, 74(6):1491-9

PubMed: 21553813 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description

Features

Displays very low toxicity toward normal cells.

Targets

HSP90 ^[1]
(Cell-free assay)

5 nM

In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. ^[1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. ^[2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
A549	MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzJTWM2OD1yLkCwNFMxOyEQvF2=	NILlSWhUSU6JRWK=
IST-MEL1	NEXkW2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDVZ40{UUN3ME2wMlAxODRyNzFOwG0>	MVTTRW5ITVJ?
NCI-SNU-1	Mk[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTlTGx[UUN3ME2wMlAxOjB5IN88US=>	M{fqdnNCVkeHUh?=
FADU	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTBwMECyNFkh\|ryP	Mk\DV2FPT0WU
C32	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnfjTWM2OD1yLkCwN\|A1KM7:TR?=	MoTKV2FPT0WU
D-566MG	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXpTYpMUUN3ME2wMlAxOzlizszN	Mke5V2FPT0WU
LXF-289	NV;FXGpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2fubWlEPTB;MD6wNFQyQSEQvF2=	MmjKV2FPT0WU
HGC-27	NIXsVlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M174VWlEPTB;MD6wNFUyKM7:TR?=	Mk\UV2FPT0WU
RPMI-7951	NXfTR49HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTBwMEC3NVch\|ryP	M2SybXNCVkeHUh?=
HSC-3	MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoD5TWM2OD1yLkCwPVI6KM7:TR?=	MljqV2FPT0WU
MIA-PaCa-2	NEXWXHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTyTWM2OD1yLkCxNFA6KM7:TR?=	MUjTRW5ITVJ?
KS-1	NVz5WlBvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTBwMEGzOVUh\|ryP	NXXn[3N2W0GQR1XS
CAL-51	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7tTWM2OD1yLkCxOFA2KM7:TR?=	NUfKdHhwW0GQR1XS
MDA-MB-361	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnhTZdKSzVyPUCuNFE1QTVizszN	NIThcWtUSU6JRWK=
TI-73	NHLCUW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnyTWM2OD1yLkCxO\|k3KM7:TR?=	MmL4V2FPT0WU
AGS	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTBwMEG5N\|gh\|ryP	MXnTRW5ITVJ?
NCI-H460	MmC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fN[2lEPTB;MD6wNVk4PCEQvF2=	MoKzV2FPT0WU
A204	MkHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1yzWWlEPTB;MD6wNlI1QSEQvF2=	NGL5V3FUSU6JRWK=
CHL-1	NEW1cnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjZToxqUUN3ME2wMlAzOjVzIN88US=>	NIfLVo5USU6JRWK=
DU-4475	MmPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3PjbGlEPTB;MD6wNlI3OSEQvF2=	NEm0ZYhUSU6JRWK=
CGTH-W-1	M4PleWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYOwUGFNUUN3ME2wMlAzOzR7IN88US=>	M3zKbnNCVkeHUh?=
HCC2218	M3TzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjpSXltUUN3ME2wMlAzPDl2IN88US=>	Mn;WV2FPT0WU
A2780	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfuO20zUUN3ME2wMlAzPTNzIN88US=>	NUfyNmc3W0GQR1XS
NCI-H720	MnHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTBwMEK1OFYh\|ryP	NWnZNVg5W0GQR1XS
NCI-N87	NGe3T3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHn2VmhKSzVyPUCuNFI2QTNizszN	M3HxXXNCVkeHUh?=
CHP-212	M4PqdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTBwMEK2Nlgh\|ryP	MWLTRW5ITVJ?
NCI-H23	MnrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37HTWlEPTB;MD6wNlY3PSEQvF2=	NXK0TFFCW0GQR1XS
D-263MG	NEW3NlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInESWVKSzVyPUCuNFI4QDZizszN	NX;ndG9WW0GQR1XS
ME-180	NGPZ[2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYK2V5I5UUN3ME2wMlAzQDlzIN88US=>	MVnTRW5ITVJ?
SW982	MlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTBwMEK5PVkh\|ryP	NXrWW3ZoW0GQR1XS
OE19	M2XHcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTBwMEOwO\|ch\|ryP	NYe2VI5bW0GQR1XS
SK-LU-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIryZYJKSzVyPUCuNFMxQDJizszN	Mmn0V2FPT0WU
H4	M1;HSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2D5c2lEPTB;MD6wN\|A6KM7:TR?=	MkHUV2FPT0WU
HT-144	NGHVUFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTBwMEOwPVMh\|ryP	NUi5SppGW0GQR1XS
SK-UT-1	NF\2UmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTBwMEOxO\|gh\|ryP	Mn3UV2FPT0WU
D-336MG	MkS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnf1TWM2OD1yLkCzN\|A6KM7:TR?=	NHXnWHhUSU6JRWK=
MDA-MB-175-VII	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPMTWM2OD1yLkCzN\|U1KM7:TR?=	NHzwZZVUSU6JRWK=
GAMG	Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vlV2lEPTB;MD6wN\|Q{PSEQvF2=	MWfTRW5ITVJ?
CP50-MEL-B	M1\QTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLPcVI4UUN3ME2wMlA{PDVizszN	MUjTRW5ITVJ?
OVCAR-5	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnQTmxGUUN3ME2wMlA{PDhizszN	M1TNVXNCVkeHUh?=
SK-MES-1	NUHSPYp4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3O5RmlEPTB;MD6wN\|YxPiEQvF2=	M3TFdXNCVkeHUh?=
VM-CUB-1	NH3PUmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXkfGpKSzVyPUCuNFM3PTdizszN	MXzTRW5ITVJ?
WM-115	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{nKRmlEPTB;MD6wN\|c3OiEQvF2=	NGPJVmxUSU6JRWK=
DSH1	NE[5WY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTBwMEO4NFch\|ryP	NGnHfFFUSU6JRWK=
Becker	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;XZWlEPTB;MD6wN\|g5PSEQvF2=	MUHTRW5ITVJ?
SW962	NYHpNZR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXL2emtDUUN3ME2wMlA{QTR3IN88US=>	NEm5dFNUSU6JRWK=
TYK-nu	M{XYRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfiTWM2OD1yLkCzPVg2KM7:TR?=	NXrWWnNFW0GQR1XS
HO-1-N-1	Mn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTBwMESwNlEh\|ryP	MUHTRW5ITVJ?
T98G	M3HDcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfvTWM2OD1yLkC0NVA{KM7:TR?=	NVPwdllEW0GQR1XS
ACN	M4PTNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTBwMESxOlIh\|ryP	MWnTRW5ITVJ?
SW780	NFPHN4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M361WWlEPTB;MD6wOFIxOyEQvF2=	NW\afVlZW0GQR1XS
Detroit562	MkSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HvV2lEPTB;MD6wOFI{QSEQvF2=	MVzTRW5ITVJ?
BB49-HNC	Mmf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTBwMESyOFMh\|ryP	MnnBV2FPT0WU
HN	MlLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;ST4ZKSzVyPUCuNFQzPzJizszN	MWXTRW5ITVJ?
H9	NHjuSGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TnOGlEPTB;MD6wOFM4OSEQvF2=	NXvsUHUyW0GQR1XS
VA-ES-BJ	M1PIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPOTWM2OD1yLkC0OFQ4KM7:TR?=	NXTEPHFkW0GQR1XS
MEL-JUSO	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjJ[WdKSzVyPUCuNFQ1PzVizszN	M3\PUnNCVkeHUh?=
BT-474	Mlj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XkWWlEPTB;MD6wOFUh\|ryP	MX7TRW5ITVJ?
CaR-1	MnLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU[yS5R3UUN3ME2wMlA1PTR7IN88US=>	NX;rbWtiW0GQR1XS
PSN1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1G1eGlEPTB;MD6wOFYxOyEQvF2=	M4f6fHNCVkeHUh?=
KYSE-510	NEjDVmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nI[mlEPTB;MD6wOFY1QSEQvF2=	NHTMdnZUSU6JRWK=
KP-4	NXjKSYU{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\BVGFGUUN3ME2wMlA1PzV\|IN88US=>	MkjZV2FPT0WU
KYSE-410	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jJW2lEPTB;MD6wOFc4OiEQvF2=	MUTTRW5ITVJ?
G-402	NY\tVG44T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHKTWM2OD1yLkC0O\|g6KM7:TR?=	MljWV2FPT0WU
DOK	MmW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTBwMES5NFIh\|ryP	MlfWV2FPT0WU
COR-L88	M2\Pbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vhVWlEPTB;MD6wOFkyOiEQvF2=	NF75NGFUSU6JRWK=
SKG-IIIa	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrzS5VKSzVyPUCuNFQ6QDZizszN	MUTTRW5ITVJ?
AN3-CA	M4XJeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFn6OI1KSzVyPUCuNFUh\|ryP	NXXzXIFxW0GQR1XS
SW48	NXH2eHNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoG1TWM2OD1yLkC1NFM6KM7:TR?=	MnvHV2FPT0WU
YKG-1	MnPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlG4TWM2OD1yLkC1NFcyKM7:TR?=	NEH4NHZUSU6JRWK=
KYSE-150	MlLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHsb5NKSzVyPUCuNFUzOzVizszN	NYLScpVVW0GQR1XS
HuO-3N1	MmmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTBwMEWyN\|ch\|ryP	MUfTRW5ITVJ?
LB1047-RCC	M2iwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTBwMEWyPVYh\|ryP	MXTTRW5ITVJ?
NCI-H2030	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLyNYpyUUN3ME2wMlA2PDF2IN88US=>	M3TqdHNCVkeHUh?=
YH-13	MoHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\DOW1KSzVyPUCuNFU4OjJizszN	MorQV2FPT0WU
5637	M1:0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M132OWlEPTB;MD6wOVc1KM7:TR?=	MmjZV2FPT0WU
LOXIMVI	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnW0TWM2OD1yLkC1PFczKM7:TR?=	NHr0fHlUSU6JRWK=
GT3TKB	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\oZodKSzVyPUCuNFU6PDJizszN	NELGVJhUSU6JRWK=
TCCSUP	NXKzWmN6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTBwMEW5OlQh\|ryP	MnvyV2FPT0WU
EPLC-272H	NGrXZYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TpTGlEPTB;MD6wOlIxPSEQvF2=	NYK5eY9rW0GQR1XS
LU-99A	M{jS[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvtS3doUUN3ME2wMlA3OjN5IN88US=>	NHz6TpRUSU6JRWK=
NCI-H1755	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInBOYdKSzVyPUCuNFY{PDFizszN	NUG2OoNPW0GQR1XS
KM12	M2S4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTBwME[zOFgh\|ryP	NUnzcZVHW0GQR1XS
SF295	M4HDcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17SXGlEPTB;MD6wOlQ2OiEQvF2=	MXjTRW5ITVJ?
MZ2-MEL	MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTBwME[1OVMh\|ryP	NVnsTmhvW0GQR1XS
HEC-1	Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIT3e5FKSzVyPUCuNFY2QDhizszN	NWez[Wd6W0GQR1XS
SW684	NFnaV4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLVTWM2OD1yLkC2OVkyKM7:TR?=	MknrV2FPT0WU
SF539	NUXYW5NmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7jTWM2OD1yLkC2OlgyKM7:TR?=	MnnXV2FPT0WU
GMS-10	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTFToRKSzVyPUCuNFY3QTlizszN	NX\6bHFqW0GQR1XS
MV-4-11	NV7sOYt4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\3TWM2OD1yLkC2PFA{KM7:TR?=	MXfTRW5ITVJ?
HT-29	M{\u[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HFU2lEPTB;MD6wOlkyQSEQvF2=	MoHrV2FPT0WU
23132-87	NH23XmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofkTWM2OD1yLkC2PVUh\|ryP	MVfTRW5ITVJ?
SW620	NHrzdZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYXaXnVWUUN3ME2wMlA4ODJ4IN88US=>	NHSxXFlUSU6JRWK=
HCC1806	MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTBwMEexN\|Eh\|ryP	MX;TRW5ITVJ?
Hs-578-T	NYPybHRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTBwMEeyNFgh\|ryP	MXfTRW5ITVJ?
A2058	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXGTWM2OD1yLkC3NlI5KM7:TR?=	MoTNV2FPT0WU
MEL-HO	NW\lS2RjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1OzdWlEPTB;MD6wO\|I2PSEQvF2=	MmrwV2FPT0WU
HCC2998	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYq2W\|JFUUN3ME2wMlA4OzR5IN88US=>	NGHPWlNUSU6JRWK=
HuO9	M3;IRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwMEe1PFkh\|ryP	MV;TRW5ITVJ?
CAL-39	MmS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3f4cmlEPTB;MD6wO\|c3PiEQvF2=	M1HPSXNCVkeHUh?=
M14	NUDrTlU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rIbGlEPTB;MD6wO\|kyOyEQvF2=	NXTIbm9PW0GQR1XS
BFTC-909	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;4WGlEPTB;MD6wO\|k3QSEQvF2=	M1nSPXNCVkeHUh?=
TE-11	NWDqUIhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;RTWM2OD1yLkC3PVk3KM7:TR?=	MkXuV2FPT0WU
TGBC1TKB	M4TId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHjTWM2OD1yLkC4NFQ{KM7:TR?=	MXfTRW5ITVJ?
L-363	M3rYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTBwMEiyNFYh\|ryP	MVHTRW5ITVJ?
A431	NXLwbGtiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHDcnJKSzVyPUCuNFgzOSEQvF2=	MVXTRW5ITVJ?
MKN45	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTBwMEiyNVkh\|ryP	NVSzOXZIW0GQR1XS
HT-1080	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTBwMEi0N\|kh\|ryP	MlLSV2FPT0WU
OVCAR-8	NWLEXoRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPmR5FOUUN3ME2wMlA5PjJ{IN88US=>	MoX3V2FPT0WU
LCLC-97TM1	NHjTe5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrveIdEUUN3ME2wMlA5PzJ6IN88US=>	NGO3cXVUSU6JRWK=
M059J	M1u3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjNXFlKSzVyPUCuNFkxOjdizszN	NX\4e\|lKW0GQR1XS
SK-MEL-2	MkjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TkOmlEPTB;MD6wPVA3KM7:TR?=	NWXZcYhpW0GQR1XS
TE-1	NWfHdYk1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDpXoFWUUN3ME2wMlA6OjB2IN88US=>	MXPTRW5ITVJ?
KYSE-180	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwMEmyOlIh\|ryP	NVKyc49IW0GQR1XS
D-247MG	NYDFd2FRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\GTWM2OD1yLkC5OFU2KM7:TR?=	NIXOcppUSU6JRWK=
8-MG-BA	MknrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTBwMEm0O\|Ih\|ryP	M33jSHNCVkeHUh?=
NCI-H1792	NH7OVmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;BTWM2OD1yLkC5OlE5KM7:TR?=	MVTTRW5ITVJ?
MCF7	NYfXU5E{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLBTWM2OD1yLkC5Olc4KM7:TR?=	NVmwUlZDW0GQR1XS
NCI-H2122	MmLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTBwMEm3OFUh\|ryP	MlX1V2FPT0WU
EFO-27	NX3wSGlFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXjXVJKSzVyPUCuNFk6QTdizszN	Ml\nV2FPT0WU
LB2241-RCC	M3za[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHuTWM2OD1yLkGwNFU1KM7:TR?=	MXzTRW5ITVJ?
SN12C	MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3Xi[GlEPTB;MD6xNFExPyEQvF2=	NGfaVHZUSU6JRWK=
A498	NHu1NlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnzcZZVUUN3ME2wMlExOThizszN	NX7oelNNW0GQR1XS
PANC-03-27	NGPrWVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTMTWM2OD1yLkGwNlg3KM7:TR?=	MULTRW5ITVJ?
NCI-H1581	NEHMW4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTBwMUCyPUDPxE1?	M3;3SnNCVkeHUh?=
U-87-MG	NFnCOldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;xcXpTUUN3ME2wMlExOzB5IN88US=>	NYjtO2pDW0GQR1XS
G-401	M4LsbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnFOHhMUUN3ME2wMlExOzV\|IN88US=>	MVTTRW5ITVJ?
SiHa	M{jBfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTBwMUC0PFYh\|ryP	NVLOPXV{W0GQR1XS
U251	NFHyeHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\Jb5pXUUN3ME2wMlExPTJ3IN88US=>	NH7TbJhUSU6JRWK=
MMAC-SF	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLCTWM2OD1yLkGwOVMyKM7:TR?=	MkfqV2FPT0WU
BB65-RCC	NETZVYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;hcGxZUUN3ME2wMlExPTV2IN88US=>	NEixdGpUSU6JRWK=
NKM-1	NIjaNoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLxbY1sUUN3ME2wMlExPjZ4IN88US=>	M1LPV3NCVkeHUh?=
HD-MY-Z	MoXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDhfYpKSzVyPUCuNVA5PzNizszN	NH;5dpdUSU6JRWK=
TGBC11TKB	NYD3NGZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3n6PWlEPTB;MD6xNFkxOyEQvF2=	M4D5[3NCVkeHUh?=
COLO-679	NWe3PVZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rpR2lEPTB;MD6xNVIyOSEQvF2=	M1HPOnNCVkeHUh?=
TE-8	NX64T\|k5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjufmxKSzVyPUCuNVEzPjRizszN	NF7zcFlUSU6JRWK=
SK-MEL-28	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nGWmlEPTB;MD6xNVMzOSEQvF2=	NUfI[mtyW0GQR1XS
SH-4	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17rd2lEPTB;MD6xNVM2PiEQvF2=	MVHTRW5ITVJ?
KALS-1	M3HqVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVOyXJE{UUN3ME2wMlEyOzl\|IN88US=>	NYL0eVdOW0GQR1XS
RKO	NYPXWYx3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LFeGlEPTB;MD6xNVc3PCEQvF2=	M1jqPXNCVkeHUh?=
OMC-1	NITlRpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjMWIg{UUN3ME2wMlEyPzl5IN88US=>	M17JSnNCVkeHUh?=
BT-549	NVvsUlVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvyV\|JKSzVyPUCuNVE4QTlizszN	NUDONmFjW0GQR1XS
NCI-H28	MnH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTBwMUG4NVch\|ryP	NUHVTmdHW0GQR1XS
RXF393	NF7GeVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHH[4xKSzVyPUCuNVE6QDJizszN	Mny2V2FPT0WU
COLO-829	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGDpd5hKSzVyPUCuNVIxODVizszN	NILxOWFUSU6JRWK=
HMV-II	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XrVmlEPTB;MD6xNlAzKM7:TR?=	M4D3cXNCVkeHUh?=
SW1990	NHztfYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrNbXFKSzVyPUCuNVIyPTdizszN	NX;PemRiW0GQR1XS
NCI-H1437	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrwO3hKSzVyPUCuNVIyPTdizszN	MmPpV2FPT0WU
SNB75	NV[4O3JlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjGPWRKSzVyPUCuNVIyPjlizszN	NETU[oRUSU6JRWK=
EW-3	MonxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoW3TWM2OD1yLkGyOlYyKM7:TR?=	MorJV2FPT0WU
SAS	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrYRYRTUUN3ME2wMlEzPjlizszN	MX3TRW5ITVJ?
NCI-H1666	NY[zUJdRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\FZWhbUUN3ME2wMlEzPzd2IN88US=>	M2LGenNCVkeHUh?=
A375	M4nod2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnuxTWM2OD1yLkGyO\|c5KM7:TR?=	MoTrV2FPT0WU
CAMA-1	NWKxW4R{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYP3WWZRUUN3ME2wMlEzQTJ2IN88US=>	MmLSV2FPT0WU
HuP-T4	M1T2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTBwMUK5OFMh\|ryP	NYrDNWJXW0GQR1XS
NCI-H292	NYjEOnprT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWD0WJFLUUN3ME2wMlE{OTFizszN	MkDNV2FPT0WU
PC-14	M13sS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M365WWlEPTB;MD6xN\|IyOSEQvF2=	NXLSeIxwW0GQR1XS
BPH-1	MoDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofRTWM2OD1yLkGzOFEh\|ryP	MkDMV2FPT0WU
GAK	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnB[4ZWUUN3ME2wMlE{PTZ5IN88US=>	MkjIV2FPT0WU
VMRC-RCZ	MkLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTBwMUO3OlIh\|ryP	MVzTRW5ITVJ?
SK-MEL-24	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTHTWM2OD1yLkGzPFch\|ryP	MVrTRW5ITVJ?
LB831-BLC	M4WzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1Hl[mlEPTB;MD6xN\|g5OyEQvF2=	NIPmbVlUSU6JRWK=
NCI-H2452	Mn\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfNTWM2OD1yLkGzPVU3KM7:TR?=	M321VHNCVkeHUh?=
RT-112	MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3VWFVtUUN3ME2wMlE1ODN3IN88US=>	M1PET3NCVkeHUh?=
GP5d	Mm\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjvOppuUUN3ME2wMlE1OTB2IN88US=>	M{XxeXNCVkeHUh?=
LC-2-ad	NIfNNGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmOyTWM2OD1yLkG0NVIyKM7:TR?=	NWDtOYE1W0GQR1XS
MPP-89	M1fJeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTBwMUSxNlUh\|ryP	MYXTRW5ITVJ?
NUGC-3	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmS3TWM2OD1yLkG0OFc5KM7:TR?=	NYDiZ4l3W0GQR1XS
GI-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTBwMUS1OVgh\|ryP	Ml\CV2FPT0WU
HCC1419	NXzXU4NPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTBwMUS1O\|Yh\|ryP	M4\6VnNCVkeHUh?=
SW1573	M3nXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjkXIJKSzVyPUCuNVQ4PThizszN	MV3TRW5ITVJ?
NCI-H2347	Ml[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LLcWlEPTB;MD6xOFg{QSEQvF2=	NGjhcoRUSU6JRWK=
Mewo	MmDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnxTWM2OD1yLkG0PFg6KM7:TR?=	MWjTRW5ITVJ?
639-V	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPNTWM2OD1yLkG1NFE{KM7:TR?=	NELPToxUSU6JRWK=
AsPC-1	NFmzeJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;vfINKSzVyPUCuNVUzOjVizszN	MnLnV2FPT0WU
NCI-H1648	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoT4TWM2OD1yLkG1NlMzKM7:TR?=	NGrGendUSU6JRWK=
786-0	NWK0VoZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;5WGlEPTB;MD6xOVM5OSEQvF2=	M4D6W3NCVkeHUh?=
ETK-1	MlXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnu1TWM2OD1yLkG1PUDPxE1?	MkLXV2FPT0WU
BxPC-3	M4Hrfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTTSVVQUUN3ME2wMlE2QTZ4IN88US=>	NV;CfJNQW0GQR1XS
CAL-62	NF30fWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTBwMU[xOlkh\|ryP	M2\5WnNCVkeHUh?=
HCC1937	NVPBOWd3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\HTWM2OD1yLkG2Nlc2KM7:TR?=	M3i5d3NCVkeHUh?=
NCI-H1299	M1myZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTBwMU[yPFUh\|ryP	MX7TRW5ITVJ?
SW1088	NIW1d3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTBwMU[0NVMh\|ryP	NYPjUFd1W0GQR1XS
FTC-133	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PPfWlEPTB;MD6xOlU1KM7:TR?=	M{[2OnNCVkeHUh?=
OC-314	NIO5eY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3O4WmlEPTB;MD6xOlY6KM7:TR?=	MWLTRW5ITVJ?
SCC-9	NVLuephpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XpN2lEPTB;MD6xOlcyPiEQvF2=	MUDTRW5ITVJ?
HT-1376	M2[2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGqzPWRKSzVyPUCuNVY6OzZizszN	NXe5N2tyW0GQR1XS
U-2-OS	MnvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2WybmlEPTB;MD6xO\|E4OyEQvF2=	MX3TRW5ITVJ?
COLO-824	MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;INmlEPTB;MD6xO\|I6PCEQvF2=	MXjTRW5ITVJ?
BB30-HNC	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nHZmlEPTB;MD6xO\|M{KM7:TR?=	NXvMZVlFW0GQR1XS
NCI-H2087	MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnEe2JKSzVyPUCuNVc{PjhizszN	NIXyem9USU6JRWK=
NCI-H2170	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHoW3VKSzVyPUCuNVc2OzZizszN	NELFWmxUSU6JRWK=
SK-OV-3	NYjHfmI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2raS2lEPTB;MD6xO\|U4OSEQvF2=	MmnjV2FPT0WU
MZ7-mel	NXT1eW8{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlftTWM2OD1yLkG3OlQ6KM7:TR?=	MW\TRW5ITVJ?
NCI-H650	M4fHXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTk[FVKSzVyPUCuNVc3QDJizszN	MVHTRW5ITVJ?
KOSC-2	NUHKVYJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTBwMUe3N\|Qh\|ryP	MoLVV2FPT0WU
SCC-4	NUHBZolNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULr[G1TUUN3ME2wMlE4Pzd5IN88US=>	NWTjZZlKW0GQR1XS
MDA-MB-157	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnOO5JzUUN3ME2wMlE5ODh{IN88US=>	M2H3[nNCVkeHUh?=
KYSE-520	MorIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjjeIRKSzVyPUCuNVgzKM7:TR?=	MXvTRW5ITVJ?
LK-2	MmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDDSmNKSzVyPUCuNVg{ODNizszN	NIC0PFJUSU6JRWK=
KNS-81-FD	MoOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvwTWM2OD1yLkG4N\|k1KM7:TR?=	M1PHcXNCVkeHUh?=
IGROV-1	M4\HeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmntTWM2OD1yLkG4OFQ{KM7:TR?=	Mki4V2FPT0WU
DEL	NVzYfJNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTBwMUi0OUDPxE1?	NI\UWYdUSU6JRWK=
NCI-H1395	MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DtR2lEPTB;MD6xPFY5OiEQvF2=	MkfoV2FPT0WU
JEG-3	NV2w[mpQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTBwMUi3NFUh\|ryP	NXLrU\|gzW0GQR1XS
BCPAP	M{TLb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILFSXBKSzVyPUCuNVg5PzJizszN	NELtWZFUSU6JRWK=
CAL-27	NIjkXmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XmZWlEPTB;MD6xPVAzOiEQvF2=	MkPTV2FPT0WU
RD	NHuyPW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW[zNYpOUUN3ME2wMlE6OTF\|IN88US=>	Ml7YV2FPT0WU
RVH-421	NWDUPG9LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEC0UWlKSzVyPUCuNVkyOTZizszN	M4PHd3NCVkeHUh?=
Capan-2	MlTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPlSXhKSzVyPUCuNVkzPTZizszN	NVrHfnZ[W0GQR1XS
COLO-680N	NYHoVldjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIf3Uo9KSzVyPUCuNVk{PjRizszN	MV;TRW5ITVJ?
NCI-H1650	NIjoSnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jzbGlEPTB;MD6yNFA2PyEQvF2=	MYPTRW5ITVJ?
SBC-5	M{PrdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1rvfmlEPTB;MD6yNFEyQCEQvF2=	M1;vNnNCVkeHUh?=
U031	NF7LRllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorJTWM2OD1yLkKwOVQ4KM7:TR?=	MXvTRW5ITVJ?
S-117	M4LUV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjpUFZuUUN3ME2wMlIxPTZ2IN88US=>	NH;TdXRUSU6JRWK=
DoTc2-4510	M4q3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjZT3ZWUUN3ME2wMlIxPzZ7IN88US=>	NVeyXlZ2W0GQR1XS
AM-38	NVLCSYhJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFT4NYNKSzVyPUCuNlA5PDhizszN	MVPTRW5ITVJ?
A172	NYHBXWhOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rkWGlEPTB;MD6yNVAzOiEQvF2=	NFHBcmdUSU6JRWK=
HPAF-II	NEfKU25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrvWoFKSzVyPUCuNlEzPjRizszN	MY\TRW5ITVJ?
769-P	NYftR2ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTlTWM2OD1yLkKxNlgh\|ryP	MYHTRW5ITVJ?
MFE-280	MoXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH:wOmpKSzVyPUCuNlEzQThizszN	NED2VJhUSU6JRWK=
TE-9	M3O1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\vTWRKSzVyPUCuNlE4QDZizszN	MYTTRW5ITVJ?
C2BBe1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LZUGlEPTB;MD6yNlE6KM7:TR?=	MW\TRW5ITVJ?
EoL-1-cell	MkjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTBwMkKyNFMh\|ryP	M4LPS3NCVkeHUh?=
G-361	NET6SFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nM[2lEPTB;MD6yNlY5OiEQvF2=	M2HWZXNCVkeHUh?=
KYSE-270	MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXi[nZEUUN3ME2wMlI{ODh2IN88US=>	NIDIO2JUSU6JRWK=
TK10	NITkOGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jmWmlEPTB;MD6yN\|EyPyEQvF2=	NYDZ[2NUW0GQR1XS
ML-2	M4flfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mkj6TWM2OD1yLkKzNVE6KM7:TR?=	NFHPc\|dUSU6JRWK=
MHH-ES-1	M{XY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3ETWM2OD1yLkKzOlgyKM7:TR?=	NH23ZmJUSU6JRWK=
BHY	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXHN4JKSzVyPUCuNlM3QTFizszN	NUDHTY9uW0GQR1XS
LS-513	NXe0[\|RbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjoTWM2OD1yLkKzPVYyKM7:TR?=	NYfZWXk1W0GQR1XS
COLO-678	MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHDTWM2OD1yLkK0NFQ1KM7:TR?=	MofyV2FPT0WU
NCI-H747	M336Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVruVIZ1UUN3ME2wMlI1OTZ7IN88US=>	MV;TRW5ITVJ?
K5	NICwNFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M134Z2lEPTB;MD6yOFM5KM7:TR?=	MWDTRW5ITVJ?
OS-RC-2	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILxWJVKSzVyPUCuNlQ2ODlizszN	Mn3sV2FPT0WU
KINGS-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDuTWM2OD1yLkK0OVI6KM7:TR?=	NXW2VldRW0GQR1XS
SCC-25	M3\ET2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnT6TWM2OD1yLkK0OVY{KM7:TR?=	Mmr0V2FPT0WU
CAPAN-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTBwMkS3PFMh\|ryP	NHHxOYVUSU6JRWK=
ESS-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHQR5BKSzVyPUCuNlQ5ODVizszN	MkPWV2FPT0WU
TE-6	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfsRlI1UUN3ME2wMlI2PzVizszN	NWrqU2JyW0GQR1XS
LB2518-MEL	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXKO4ZKSzVyPUCuNlU4PzdizszN	M3jTVXNCVkeHUh?=
COLO-800	NWntWZFLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3KdXFKSzVyPUCuNlU5OTJizszN	MmDTV2FPT0WU
LU-134-A	MmXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjkb3hKSzVyPUCuNlYyOzZizszN	NVO1WGtYW0GQR1XS
NCI-H1155	NXruPGtvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXT2O5ROUUN3ME2wMlI3OTZ{IN88US=>	M{jEZXNCVkeHUh?=
MFM-223	Mn\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnSTJNKSzVyPUCuNlY{PjNizszN	MnLOV2FPT0WU
HTC-C3	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXm0OG5lUUN3ME2wMlI3PTB4IN88US=>	MWnTRW5ITVJ?
HCT-116	MoS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLvPIFKSzVyPUCuNlY2QTlizszN	MkHkV2FPT0WU
Ca-Ski	M32zbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXETWM2OD1yLkK2Olc5KM7:TR?=	NW\YRYRPW0GQR1XS
SBC-1	NWC3SJNjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDZV4FPUUN3ME2wMlI3PzR{IN88US=>	MWPTRW5ITVJ?
NB69	M3\ifWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHzR2RpUUN3ME2wMlI4ODh5IN88US=>	Ml22V2FPT0WU
J82	NFvRSYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVWzUFZLUUN3ME2wMlI4OjZ3IN88US=>	MlrEV2FPT0WU
U-118-MG	M{e1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTBwMke1O\|kh\|ryP	NGTPUXdUSU6JRWK=
NCI-H1355	MoPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFznUVNKSzVyPUCuNlgxPzRizszN	MV7TRW5ITVJ?
NCI-H1048	MmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rDT2lEPTB;MD6yPFk2PiEQvF2=	MXHTRW5ITVJ?
SW954	MkDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTBwMkmyNlch\|ryP	NFvPW21USU6JRWK=
NMC-G1	MoDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17NXWlEPTB;MD6yPVI4PyEQvF2=	M{P0fXNCVkeHUh?=
SW1710	M4Dn[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXKTWM2OD1yLkK5OFk1KM7:TR?=	NFW1d3BUSU6JRWK=
KY821	NGfFWHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULzdXlIUUN3ME2wMlI6QDd{IN88US=>	NWqwPIhJW0GQR1XS
HCC38	NGPxU4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTBwM{CwO\|gh\|ryP	NUP3fFM2W0GQR1XS
NCI-SNU-5	NFjQUXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DTTmlEPTB;MD6zNFU1KM7:TR?=	Mon6V2FPT0WU
ES8	NGf1bW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\r[2lEPTB;MD6zNFc5PCEQvF2=	NIPTcXZUSU6JRWK=
COLO-792	NYHqRlVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTBwM{GyOVEh\|ryP	NFH6ZnhUSU6JRWK=
BFTC-905	M2LVS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NICybY5KSzVyPUCuN\|E2OjFizszN	MknLV2FPT0WU
ChaGo-K-1	NWLMS4J3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\Be2lKSzVyPUCuN\|E4OTVizszN	NYjLR2RSW0GQR1XS
Daoy	MkLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvHNmdPUUN3ME2wMlMyPzJ\|IN88US=>	MYjTRW5ITVJ?
SJSA-1	NWLNS3E1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIGxNotKSzVyPUCuN\|E5PDdizszN	M2fxdnNCVkeHUh?=
KNS-62	M325W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrGTWM2OD1yLkOyNFg5KM7:TR?=	NGTtV3ZUSU6JRWK=
CAKI-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkL3TWM2OD1yLkOyNVEyKM7:TR?=	MnSzV2FPT0WU
UACC-62	NWfNbmJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTBwM{KyNlch\|ryP	NIn3coRUSU6JRWK=
HuCCT1	MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHTVoVKSzVyPUCuN\|IzQDNizszN	MkXiV2FPT0WU
CTB-1	MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DMWmlEPTB;MD6zNlc2OyEQvF2=	MlHCV2FPT0WU
NTERA-S-cl-D1	M2Hme2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzqTWM2OD1yLkOyPFM3KM7:TR?=	NFHOXY5USU6JRWK=
T-24	NXXvV\|JwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;DRpN6UUN3ME2wMlM{OTV7IN88US=>	MV;TRW5ITVJ?
KYSE-70	NYnNVJRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFu0NVNKSzVyPUCuN\|MzQDNizszN	NGn6Z41USU6JRWK=
SW626	NYLkOZJOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTBwM{O1N\|Ih\|ryP	Mo[3V2FPT0WU
LB996-RCC	MojsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLOTWM2OD1yLkOzOlE6KM7:TR?=	NH3X[W5USU6JRWK=
DMS-273	NHnWRVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTBwM{O5NVYh\|ryP	NVLz[HJLW0GQR1XS
SW1783	MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTBwM{O5PVch\|ryP	NWfIXXhyW0GQR1XS
KU812	NH3vZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTBwM{SwN\|gh\|ryP	NWPHSXI1W0GQR1XS
HSC-2	M1fx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnCVnJuUUN3ME2wMlM1ODV\|IN88US=>	M{jUO3NCVkeHUh?=
A3-KAW	NHfwWlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTBwM{SxOlIh\|ryP	NV7Qc3h7W0GQR1XS
COLO-684	M4\nUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDINWMzUUN3ME2wMlM1PTBzIN88US=>	NH3NSJFUSU6JRWK=
NCI-H2405	NV;FdlRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\u[GlEPTB;MD6zOFY{OSEQvF2=	MWPTRW5ITVJ?
NCI-H2228	M4LBRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXLS2tKSzVyPUCuN\|U{PTdizszN	MWfTRW5ITVJ?
NB13	NWriV2lkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4njRmlEPTB;MD6zOlgzQSEQvF2=	NXzYV5VUW0GQR1XS
no-11	M1jDTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzV[3lUUUN3ME2wMlM3QTVizszN	MXLTRW5ITVJ?
DK-MG	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HvT2lEPTB;MD6zO\|E5QCEQvF2=	MYHTRW5ITVJ?
NBsusSR	NFvwb3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTBwM{eyPFUh\|ryP	NILTPGxUSU6JRWK=
KP-N-YS	NXTFU2k5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlj2TWM2OD1yLkO3OFY{KM7:TR?=	NHHyeI1USU6JRWK=
CFPAC-1	NIrnZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTBwM{e1NVgh\|ryP	MUfTRW5ITVJ?
KARPAS-45	M2fqWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHKZY1UUUN3ME2wMlM4QDZ{IN88US=>	NWnydmN1W0GQR1XS
NCI-H1793	M4W5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\6ZoJCUUN3ME2wMlM5PTFizszN	M3q0SnNCVkeHUh?=
HCE-T	MojYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFf6XXpKSzVyPUCuN\|g3ODNizszN	NX\peWFSW0GQR1XS
NCI-H520	MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LKcmlEPTB;MD6zPFcxOyEQvF2=	MVjTRW5ITVJ?
HCC2157	M2HJbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M36xdmlEPTB;MD6zPFc5OSEQvF2=	NHm3bpRUSU6JRWK=
EW-18	M1O2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\sSWtKSzVyPUCuN\|g6PDFizszN	NIDUb5dUSU6JRWK=
RO82-W-1	NYKwblFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXKSXE3UUN3ME2wMlM6Pjl7IN88US=>	NWnuR4NGW0GQR1XS
HuP-T3	NHPsTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPIUIlMUUN3ME2wMlQxOTR\|IN88US=>	MonFV2FPT0WU
PANC-10-05	M1S5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XGNWlEPTB;MD60NVE4KM7:TR?=	NEfuZXhUSU6JRWK=
NCI-H1703	M4HvTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1jDVmlEPTB;MD60NVQ1PiEQvF2=	NIC4W49USU6JRWK=
TE-10	NUnlV4dPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{Oy[mlEPTB;MD60NVQ1PyEQvF2=	M4LmPHNCVkeHUh?=
HOS	M3PoNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVn0ZWtnUUN3ME2wMlQyPjh{IN88US=>	NIC1RpRUSU6JRWK=
LN-405	Mo[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jHZmlEPTB;MD60NVY5PyEQvF2=	NVLwV4pCW0GQR1XS
A427	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXmS5BKSzVyPUCuOFE6QDFizszN	NVjXXWJVW0GQR1XS
CAL-12T	Mo\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTBwNEK3PEDPxE1?	NFjwfm9USU6JRWK=
SW756	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLXTWM2OD1yLkS0NVg{KM7:TR?=	NYLsVoZ1W0GQR1XS
YAPC	MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHe4[2ZKSzVyPUCuOFUxQCEQvF2=	NVL5bZlwW0GQR1XS
GOTO	Mmm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnSwTWM2OD1yLkS1NVYh\|ryP	MlTzV2FPT0WU
C3A	MofWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETYPJRKSzVyPUCuOFU1OzdizszN	MoPYV2FPT0WU
UM-UC-3	NFu5XZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3f4VmlEPTB;MD60OVQ4KM7:TR?=	NUfobVJkW0GQR1XS
NCI-H1573	MkTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGr3SYxKSzVyPUCuOFU2PjlizszN	MnqzV2FPT0WU
LS-411N	M2XkeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PKXmlEPTB;MD60OlUzPyEQvF2=	NFjMVldUSU6JRWK=
COR-L23	NHe0dZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHFWWtKSzVyPUCuOFY4PjRizszN	NIrjOpZUSU6JRWK=
HCE-4	MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTBwNEe0OFYh\|ryP	NIDySpZUSU6JRWK=
NCI-H2291	MlHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTBwNEe4PVYh\|ryP	NGe1cFBUSU6JRWK=
A101D	NUfudJYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2f2cWlEPTB;MD60PFA2OyEQvF2=	M2C2WHNCVkeHUh?=
HT-3	M4jqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTmTWM2OD1yLkS4NlE4KM7:TR?=	MVnTRW5ITVJ?
HOP-62	NXP3T\|B5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTuTWM2OD1yLkS5PFY2KM7:TR?=	NFTL[YxUSU6JRWK=
PC-3	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTBwNUG1NFch\|ryP	MUfTRW5ITVJ?
CTV-1	NWjWWHBwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfPTWM2OD1yLkWyOlY6KM7:TR?=	NInHW3dUSU6JRWK=
PANC-08-13	NVXsOlhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTBwNUOxO\|ch\|ryP	NYOyclU3W0GQR1XS
CAL-120	NGX0bnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7CTWM2OD1yLkWzN\|k6KM7:TR?=	MVXTRW5ITVJ?
UMC-11	NFy1R5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\2cWlEPTB;MD61OVI{PCEQvF2=	NIn5ZmJUSU6JRWK=
MSTO-211H	M4HhVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnES\|ZLUUN3ME2wMlU2PzZ{IN88US=>	MoX6V2FPT0WU
NCI-H2126	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTBwNU[4NVUh\|ryP	MWrTRW5ITVJ?
SNU-C2B	MnnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTBwNUe5O\|ch\|ryP	MUXTRW5ITVJ?
DBTRG-05MG	M4O4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3MfplKSzVyPUCuOVgxPTNizszN	NH;ubppUSU6JRWK=
MKN1	MofJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTBwNUi3PFMh\|ryP	NVzINFRuW0GQR1XS
ES3	M4XLO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTBwNUmxNlQh\|ryP	NW\PZW9TW0GQR1XS
OVCAR-3	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFT0OlVKSzVyPUCuOVk{PDFizszN	MXrTRW5ITVJ?
ACHN	MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7M[lRKSzVyPUCuOlA2PjlizszN	NETsVnFUSU6JRWK=
SW872	NEC2WVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTBwNkC3OlMh\|ryP	MYfTRW5ITVJ?
CP66-MEL	M{TRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTBwNkC5Olkh\|ryP	NXzkdpUxW0GQR1XS
NCI-H661	M1ThOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULsVnQ1UUN3ME2wMlYyOTB2IN88US=>	Mn24V2FPT0WU
UACC-893	M4S3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXCRVhKSzVyPUCuOlM3QDFizszN	MV3TRW5ITVJ?
JVM-3	NGPYS5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzIdJlKSzVyPUCuOlM5ODRizszN	NEPlTXNUSU6JRWK=
SF268	NGDoZ4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3T4emlEPTB;MD62OFM1QSEQvF2=	M2\uOXNCVkeHUh?=
OCI-AML2	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYG4R5EzUUN3ME2wMlY2Ozl5IN88US=>	NIjIe2FUSU6JRWK=
RPMI-8226	NEOyUHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnucm9UUUN3ME2wMlY3OzJ\|IN88US=>	MlL6V2FPT0WU
MKN28	M3zycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mke3TWM2OD1yLk[2OlI1KM7:TR?=	NIjF[JVUSU6JRWK=
MDA-MB-453	NGnpV3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTBwNkexPEDPxE1?	NFW1XWFUSU6JRWK=
BV-173	NGnWT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTBwNki2O\|kh\|ryP	NY\qVGg4W0GQR1XS
NCI-H358	NF;RTIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3TJcGlEPTB;MD62PFczPiEQvF2=	MWPTRW5ITVJ?
NCI-H1651	NIX1Z\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33xZWlEPTB;MD63JO69VQ>?	NIPCUGdUSU6JRWK=
MDA-MB-415	M4rHUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDpVWNTUUN3ME2wMlcxQDJ7IN88US=>	NY\GW4MxW0GQR1XS
8305C	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTBwN{K0PVgh\|ryP	MoLPV2FPT0WU
EFM-19	NGPxN\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlX2TWM2OD1yLkezOlcyKM7:TR?=	M{izenNCVkeHUh?=
RERF-LC-MS	M2HDZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\Zb2lEPTB;MD63OFYyOyEQvF2=	MV;TRW5ITVJ?
A388	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHteJROUUN3ME2wMlc3PDZ5IN88US=>	NHTJOW1USU6JRWK=
GI-ME-N	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTBwN{eyN\|Uh\|ryP	NV7QNYpRW0GQR1XS
IGR-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVzwOlVXUUN3ME2wMlc6ODR\|IN88US=>	M335UnNCVkeHUh?=
LNCaP-Clone-FGC	M{XteWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkD2TWM2OD1yLkiwNFA1KM7:TR?=	MWLTRW5ITVJ?
SK-MEL-3	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFThSohKSzVyPUCuPFE2ODhizszN	M{jGTHNCVkeHUh?=
UACC-257	Mm[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DkOGlEPTB;MD64NlI{OSEQvF2=	NWC2V5RWW0GQR1XS
OE33	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTBwOEWxNFEh\|ryP	MWjTRW5ITVJ?
QIMR-WIL	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjLeHZKSzVyPUCuPFUyPDFizszN	NIfnWZNUSU6JRWK=
NCI-H2009	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTBwOEWzNVEh\|ryP	NV;ZeZlOW0GQR1XS
NCI-H522	NITnPXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33N[mlEPTB;MD64O\|c5OyEQvF2=	MWTTRW5ITVJ?
Saos-2	MmXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrIO49KSzVyPUCuPFc5PzFizszN	MWrTRW5ITVJ?
NB17	NH7hXXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTBwOEiwNlUh\|ryP	MkHaV2FPT0WU
D-392MG	NIHqc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHMTWM2OD1yLki5N\|U3KM7:TR?=	NHfscpRUSU6JRWK=
SHP-77	NXHKXpkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\0Smp3UUN3ME2wMlkxPDh3IN88US=>	NXW1WGxOW0GQR1XS
SK-MEL-30	MoWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzlbGRKSzVyPUCuPVEyQDVizszN	M{f4bnNCVkeHUh?=
GCIY	MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XhVmlEPTB;MD65NVg1OyEQvF2=	NHm2fnVUSU6JRWK=
HCC70	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MorkTWM2OD1yLkmyNFU6KM7:TR?=	MYrTRW5ITVJ?
LU-65	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX3Yd4tbUUN3ME2wMlkzPTlzIN88US=>	NX\ZWXRRW0GQR1XS
NCI-H1563	NWjtb3JiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrTV4VKSzVyPUCuPVQ5PjVizszN	MofQV2FPT0WU
KURAMOCHI	MnPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XsbmlEPTB;MD65OVE6OiEQvF2=	NUT5[W1oW0GQR1XS
PA-1	NV7ifoppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTBwOUW0NlQh\|ryP	Ml;mV2FPT0WU
NOS-1	NGCxVnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PB[2lEPTB;MD65O\|Q5QSEQvF2=	NF7hdGhUSU6JRWK=
NCI-H69	NIXhPW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnGbJRLUUN3ME2wMlk4PjN2IN88US=>	MV;TRW5ITVJ?
KYSE-450	M2r5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfEXXZKSzVyPUCuPVg3OjZizszN	MofuV2FPT0WU
8505C	M{jpWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2C0U2lEPTB;MD65PVk5OiEQvF2=	M3HocnNCVkeHUh?=
TGBC24TKB	NUDYWHJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHj3W\|hKSzVyPUGuNFAxQDRizszN	MVfTRW5ITVJ?
PFSK-1	MnrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HsRmlEPTB;MT6wNVQzQCEQvF2=	NXiwTnU4W0GQR1XS
EKVX	NVrUXXJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTFwMEOxNlEh\|ryP	MV;TRW5ITVJ?
RCM-1	M1rwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDoVFlnUUN3ME2xMlA2PTB5IN88US=>	NHOyO\|BUSU6JRWK=
SW900	NGXSN4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHG1WJdKSzVyPUGuNFc5OyEQvF2=	M3;RVnNCVkeHUh?=
D-542MG	M{LsVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTFwMEe4OVUh\|ryP	MVrTRW5ITVJ?
SK-PN-DW	M3:zPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzJV2dSUUN3ME2xMlExODV4IN88US=>	Mke2V2FPT0WU
NCI-H727	NI[xVJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTFwMUCxOVQh\|ryP	M2C5cHNCVkeHUh?=
SW837	M{HjSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nhOGlEPTB;MT6xNFk2PCEQvF2=	M{LmRnNCVkeHUh?=
BT-20	NIK3eFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTqWY9KSzVyPUGuNVEzODRizszN	NITJZpZUSU6JRWK=
RH-18	NX;6UVFST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PQOWlEPTB;MT6xN\|ExOyEQvF2=	M1;3WXNCVkeHUh?=
TE-12	MkLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zqZmlEPTB;MT6xN\|M{OyEQvF2=	NIPuR3ZUSU6JRWK=
NB10	MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTFwMUOzOFQh\|ryP	NWfMSWNWW0GQR1XS
AU565	M3\PWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmTCTWM2OD1zLkG1PVc{KM7:TR?=	NUXCTIF5W0GQR1XS
OAW-42	NU\XTYFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWmzfnR7UUN3ME2xMlE5OzB4IN88US=>	MWPTRW5ITVJ?
DJM-1	M2rUb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{WyS2lEPTB;MT6xPVg5OSEQvF2=	M3\ZXXNCVkeHUh?=
HH	NHzGSllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETPcJZKSzVyPUGuNlM5OzFizszN	NW\TZVdOW0GQR1XS
LAMA-84	NUjoU5BiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7KXmFKSzVyPUGuNlc{QTRizszN	M{ezZXNCVkeHUh?=
KNS-42	MojoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DoXmlEPTB;MT6zNFI6PiEQvF2=	MkG5V2FPT0WU
NCI-H2052	M4LERmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzGTWM2OD1zLkOwOVA4KM7:TR?=	MoLXV2FPT0WU
MLMA	NET5fIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTjb2hZUUN3ME2xMlMzPDB5IN88US=>	MYHTRW5ITVJ?
NB12	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTFwM{W2N\|Yh\|ryP	NYnaXlBzW0GQR1XS
NCI-H1838	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPJUFBQUUN3ME2xMlM3OzB4IN88US=>	MlzUV2FPT0WU
NCI-H526	MmjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlTETWM2OD1zLkO3PFU{KM7:TR?=	NYe0doM4W0GQR1XS
LS-123	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnjaTWM2OD1zLkO5NFk1KM7:TR?=	MYHTRW5ITVJ?
HDLM-2	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnaS5dKSzVyPUGuN\|kzPzFizszN	MWrTRW5ITVJ?
MC-IXC	Mn:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTFwNEKzO\|Eh\|ryP	NGfsXm5USU6JRWK=
HCT-15	Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{frWGlEPTB;MT60N\|A3QCEQvF2=	NFXwd4JUSU6JRWK=
NCI-H596	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFP5ZldKSzVyPUGuOFUxPjFizszN	NEG3U41USU6JRWK=
ZR-75-30	M2XsS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPiXItQUUN3ME2xMlQ4ODh{IN88US=>	NX;neFR{W0GQR1XS
A704	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojCTWM2OD1zLk[2OVY{KM7:TR?=	M1:0cXNCVkeHUh?=
OVCAR-4	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmX3TWM2OD1zLk[5OlA4KM7:TR?=	M4PX[HNCVkeHUh?=
SW1417	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TVWGlEPTB;MT63Nlg1QSEQvF2=	MoLYV2FPT0WU
CAS-1	Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvGTIxKSzVyPUGuO\|M6OzZizszN	NXS0Z4l4W0GQR1XS
IST-SL1	M3jyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfKTWM2OD1zLke5O\|U6KM7:TR?=	MnjqV2FPT0WU
A253	NHXsZo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PVVWlEPTB;MT64NlI{QSEQvF2=	NF;TNnNUSU6JRWK=
EW-16	NV\GS3o2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfzbmZKSzVyPUGuPFI5PzVizszN	MWHTRW5ITVJ?
SK-NEP-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljlTWM2OD1zLki2PVg5KM7:TR?=	M4LPRXNCVkeHUh?=
NCI-H226	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTFwOEmzOVkh\|ryP	NWr6WIdQW0GQR1XS
HOP-92	NHvSNZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7ISFJKSzVyPUGuPVYxQTlizszN	NVHN[YNVW0GQR1XS
NCI-H441	NEPQWYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXPV5FUUUN3ME2yMlAzOzN5IN88US=>	NHrqcoNUSU6JRWK=
LU-139	NVvjZXdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfXW\|N2UUN3ME2yMlA{OTF2IN88US=>	NEfsTHBUSU6JRWK=
SJRH30	MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTJwMESyOVMh\|ryP	MlTMV2FPT0WU
MG-63	M{\GVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPzNnVXUUN3ME2yMlE1OTFzIN88US=>	NEDTbGVUSU6JRWK=
NH-12	NHv3N5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3TnTGlEPTB;Mj6xOVAxPiEQvF2=	MkH6V2FPT0WU
NB7	Mnf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnOxTWM2OD1{LkG5Olc{KM7:TR?=	NX;tS5V5W0GQR1XS
LB771-HNC	M{[4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnPNmxrUUN3ME2yMlIxPTl3IN88US=>	NGjYepdUSU6JRWK=
HCC1569	MkfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmr2TWM2OD1{LkK0OVg{KM7:TR?=	NEnqeJJUSU6JRWK=
D-283MED	NFWxV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HRNmlEPTB;Mj6yOFc5OiEQvF2=	MULTRW5ITVJ?
J-RT3-T3-5	NITrfGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGX0bYVKSzVyPUKuNlU{PTFizszN	MnPNV2FPT0WU
ATN-1	MmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnywTWM2OD1{LkOzNFgzKM7:TR?=	M176ZnNCVkeHUh?=
HCC1954	NF\ySGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTJwM{S0NFgh\|ryP	MXvTRW5ITVJ?
SCC-15	NV3pW45qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XmPGlEPTB;Mj6zPVMyOiEQvF2=	MmPOV2FPT0WU
COLO-668	MorES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4K4W2lEPTB;Mj60N\|Ih\|ryP	NWX3TWwyW0GQR1XS
LB373-MEL-D	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTJwNUS2O\|ch\|ryP	Mn3pV2FPT0WU
no-10	M2ezNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDBTWM2OD1{LkW0PVQ4KM7:TR?=	MnSzV2FPT0WU
HT-1197	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnQVJVKSzVyPUKuOlMyQDhizszN	NHHCZXJUSU6JRWK=
DU-145	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTJwN{mxOlIh\|ryP	MXPTRW5ITVJ?
SK-N-AS	M1[wemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUj1XYhvUUN3ME2yMlg1Pjl{IN88US=>	M3HTOnNCVkeHUh?=
MOLT-4	Mn7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG[3bmJKSzVyPUKuPFU{OjJizszN	M3rzdnNCVkeHUh?=
EW-22	M4\1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmi2TWM2OD1{LkmyPFQyKM7:TR?=	M3\KZXNCVkeHUh?=
DB	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\vb2lKSzVyPUKuPVc4PTlizszN	MXzTRW5ITVJ?
HL-60	M1;iS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTNwMESzO\|Yh\|ryP	NYLGWm4xW0GQR1XS
SK-N-DZ	M{HiOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVy1OotvUUN3ME2zMlA2ODd3IN88US=>	NESyVYtUSU6JRWK=
NY	NYO0dVZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmThTWM2OD1\|LkC4OVQzKM7:TR?=	MVjTRW5ITVJ?
T47D	NGDocYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXINZg{UUN3ME2zMlExPTV6IN88US=>	NGXEc2ZUSU6JRWK=
NCI-H2029	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVzCWIN3UUN3ME2zMlIzPDd5IN88US=>	NWPES4xjW0GQR1XS
KARPAS-299	MlnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\3bVdTUUN3ME2zMlI3ODJ5IN88US=>	NHnXOXdUSU6JRWK=
KM-H2	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrrOmdIUUN3ME2zMlMxPjhizszN	M1XOOXNCVkeHUh?=
CHP-134	NWTSZVJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHuTGd5UUN3ME2zMlQ4OzlizszN	M2TNb3NCVkeHUh?=
22RV1	MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEi2[VRKSzVyPUOuOFkyPjhizszN	MoK3V2FPT0WU
NB5	MlnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrlTWM2OD1\|LkWwOlg6KM7:TR?=	NXvWUZBFW0GQR1XS
CW-2	MlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjZTIdNUUN3ME2zMlU2OzF2IN88US=>	NXLYV5ltW0GQR1XS
EFO-21	MlniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVf5bYJ4UUN3ME2zMlU3QTRizszN	NGf2em5USU6JRWK=
HuH-7	NYfG[\|RWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfnWolKSzVyPUOuOVg1OTRizszN	NUDJRZFGW0GQR1XS
ALL-PO	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTNwNkKzN\|Uh\|ryP	NVeyPJVtW0GQR1XS
EM-2	M1:zZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjzTWM2OD1\|Lk[5NFEyKM7:TR?=	NXTFWmx[W0GQR1XS
KLE	Mnq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nvUmlEPTB;Mz63N\|AzQSEQvF2=	M4HU[HNCVkeHUh?=
NEC8	NFnNUplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTMXlY{UUN3ME2zMlkyQDB6IN88US=>	NVH5OlVNW0GQR1XS
KP-N-YN	M{PpcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknkTWM2OD1\|LkmzOFc3KM7:TR?=	NFn2bWNUSU6JRWK=
SK-MEL-1	M3vtTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYriVVhxUUN3ME20MlA{PTF6IN88US=>	M2DkPXNCVkeHUh?=
CAL-54	NXK4SYN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHpXXprUUN3ME20MlA2QTFizszN	NVX4O5RyW0GQR1XS
MS-1	NILrfZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTRwMU[xOVUh\|ryP	MXvTRW5ITVJ?
NCI-H209	NWfqb4I1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;mVlR2UUN3ME20MlI6QTl7IN88US=>	MnPGV2FPT0WU
NOMO-1	MkHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUL3ZXhSUUN3ME20MlMzOTNzIN88US=>	NWrOdZR1W0GQR1XS
RPMI-2650	NFLiPVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILP[WZKSzVyPUSuN\|Y{OjdizszN	M2jCUXNCVkeHUh?=
NCI-H810	NGDIfVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTRwM{m3N\|Yh\|ryP	MmrBV2FPT0WU
Ca9-22	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLYeZlKSzVyPUSuOFU3QTFizszN	NI\RbnJUSU6JRWK=
ES4	NFS1[mxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTRwNEewPVUh\|ryP	NESxNIxUSU6JRWK=
ES6	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\tTWM2OD12LkS5OlU4KM7:TR?=	MWPTRW5ITVJ?
DMS-114	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTRwNUS2PVEh\|ryP	M13iSXNCVkeHUh?=
ONS-76	Mmm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGm3dVRKSzVyPUSuOVc6PSEQvF2=	MnvqV2FPT0WU
K-562	NHfl[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGflSFBKSzVyPUSuO\|M5OTRizszN	M3jUZnNCVkeHUh?=
MHH-NB-11	NUf2PYVVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rucGlEPTB;ND63OVQ3OSEQvF2=	Ml\DV2FPT0WU
Calu-3	NIf1dpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFHIOpFKSzVyPUSuO\|g2PDhizszN	MXHTRW5ITVJ?
HT55	NV3PcYJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYLkVY9IUUN3ME20Mlg1PTR3IN88US=>	NELEPXhUSU6JRWK=
SK-N-FI	MorQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzKelhiUUN3ME20Mlg2ODB7IN88US=>	NX24bIdIW0GQR1XS
ES1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrkOmZKSzVyPUSuPFYxPTdizszN	MUPTRW5ITVJ?
SF126	Ml7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rmTGlEPTB;ND65N\|E5PCEQvF2=	MXnTRW5ITVJ?
ES5	Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLBWYNGUUN3ME21MlEzPDJ5IN88US=>	M2jrXHNCVkeHUh?=
LoVo	NV;ST2ljT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTVwMUW4O\|Eh\|ryP	M4W4T3NCVkeHUh?=
SNU-387	NWPON2Y5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX71bnZoUUN3ME21MlMzOzN7IN88US=>	MXjTRW5ITVJ?
C8166	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTVwM{[zN\|kh\|ryP	NF[5O2VUSU6JRWK=
LS-1034	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnL2TWM2OD13LkSyN\|A4KM7:TR?=	NYfFVlExW0GQR1XS
GR-ST	M{H1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTVwNUKyNFEh\|ryP	MnTBV2FPT0WU
NCI-H1092	MoflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrETWM2OD13LkeyPFQ{KM7:TR?=	NILkWpdUSU6JRWK=
647-V	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIf3THhKSzVyPUWuO\|Q4ODZizszN	NIXv[5dUSU6JRWK=
EW-13	MknNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTVwN{[2Nlch\|ryP	MU\TRW5ITVJ?
KGN	NHLWPXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjFUHFKSzVyPU[uNFk6OjFizszN	NYXxeIZEW0GQR1XS
D-423MG	NF;jfHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\yVFRpUUN3ME22MlQxOjh2IN88US=>	NH64TmxUSU6JRWK=
ECC10	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG[4cVlKSzVyPUeuNVAyODFizszN	NInS[mhUSU6JRWK=
TE-5	NYLvVFlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;3VpI1UUN3ME23MlQyOjl6IN88US=>	Mlm0V2FPT0WU
P12-ICHIKAWA	NEXJfXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWCzOItlUUN3ME23MlQ2PTJ\|IN88US=>	M3\icnNCVkeHUh?=
NCI-H82	M3yze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;G[2lEPTB;Nz60OVcxOSEQvF2=	NV[1WZZFW0GQR1XS
NCI-H1993	M3TjSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTrTWM2OD15LkizNFY{KM7:TR?=	NILZXmNUSU6JRWK=
RH-1	M{WxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDQTWM2OD15Lki1NlQ1KM7:TR?=	NFrVeJdUSU6JRWK=
SW948	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vzdWlEPTB;Nz65OlA1QSEQvF2=	NYLZdm93W0GQR1XS
CAL-33	NHvKWWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLmb2hKSzVyPUeuPVk6OzhizszN	M2jwcHNCVkeHUh?=
U-266	M2e1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XtZWlEPTB;OD6xOVc4PyEQvF2=	NHjVNmFUSU6JRWK=
CAL-72	NVXhV3FRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV3VPHY1UUN3ME24MlIxOzJizszN	MoHPV2FPT0WU
SNU-423	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYO3[4dtUUN3ME25MlM3PjZ4IN88US=>	NV\xZohDW0GQR1XS
KG-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rxVWlEPTB;OT61PFQ2PiEQvF2=	M1LzTHNCVkeHUh?=
HCC1395	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLoTWM2OD17LkmyN\|UzKM7:TR?=	NXS2OW5JW0GQR1XS
BE-13	NVntNYdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rRWGlEPTB;MUCuPFg6OiEQvF2=	NYLUfGQ5W0GQR1XS
MKN7	NUDLe5ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\0cGlEPTB;MUCuPVc3PSEQvF2=	NWP6fW1JW0GQR1XS
697	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTFzLkG0O\|Ih\|ryP	MmPuV2FPT0WU
LU-135	NWnWfYVTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrVc2k2UUN3ME2xNU4zOzB5IN88US=>	NGDo[lNUSU6JRWK=
ES7	NVrncVJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVftOYo1UUN3ME2xNU4{OzF\|IN88US=>	M4LiRnNCVkeHUh?=
SK-HEP-1	NViwcpVzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7ITWM2OD1zMT63OlQ3KM7:TR?=	MWHTRW5ITVJ?
BEN	NUDuXXdiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXp[YpKSzVyPUGxMlg2OSEQvF2=	NW\vU4xRW0GQR1XS
NCI-H1770	MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrzXJdKSzVyPUGyMlEzPiEQvF2=	NVXm[lg3W0GQR1XS
SW13	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTF{LkG1OFEh\|ryP	MmfoV2FPT0WU
MZ1-PC	NVTpc4ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYjxTHY1UUN3ME2xNk42PDV{IN88US=>	NW[5ZZlsW0GQR1XS
Mo-T	Ml3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGP5SGFKSzVyPUGyMlc1OjFizszN	NWn0V\|Q1W0GQR1XS
HLE	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nFUGlEPTB;MUKuPFIyPSEQvF2=	M2jsO3NCVkeHUh?=
RCC10RGB	NF[4ZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mkm1TWM2OD1zMz62O\|Eh\|ryP	Mn;zV2FPT0WU
COLO-320-HSR	NHS1RmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPCbXJtUUN3ME2xN{44OzhzIN88US=>	M1vTZXNCVkeHUh?=
BHT-101	M332TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjYS5NKSzVyPUGzMlg{PDVizszN	NInoZXlUSU6JRWK=
OCUB-M	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTrOplKSzVyPUG0MlE3ODJizszN	MkX3V2FPT0WU
MEG-01	NIrIXGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHKbFYxUUN3ME2xOE4{PzB6IN88US=>	NUjHNYN5W0GQR1XS
RS4-11	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTF2Lke0NkDPxE1?	NG\EemFUSU6JRWK=
MN-60	M1y5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHW2VGRKSzVyPUG0Mlc5QTRizszN	NILwTYtUSU6JRWK=
NCI-H1304	NWf6XmYyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHnCZ2RKSzVyPUG1MlA1OjVizszN	NUnheG5uW0GQR1XS
Ramos-2G6-4C10	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTF3LkC1PFEh\|ryP	NGfSUVdUSU6JRWK=
NCI-H2342	M2SzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoHUTWM2OD1zNT6yNFQ1KM7:TR?=	NGfPbFJUSU6JRWK=
LAN-6	NHjFOWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrib3ZKSzVyPUG1MlQ1OTRizszN	NVTVVopJW0GQR1XS
JVM-2	M3Htdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mme2TWM2OD1zNT61O\|Q5KM7:TR?=	NXjBZZpiW0GQR1XS
P30-OHK	NEW2e2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPwTWM2OD1zNj6wOlE1KM7:TR?=	MXrTRW5ITVJ?
C-33-A	NEGzeIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XodGlEPTB;MU[uOlIyPCEQvF2=	M2fSUHNCVkeHUh?=
RPMI-8866	M{jvXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33UPGlEPTB;MU[uPFQ6PiEQvF2=	NUjGXHRqW0GQR1XS
NCI-H630	NFjreXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3TEOWlEPTB;MU[uPFU{PyEQvF2=	NFj1SZNUSU6JRWK=
KYSE-140	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrFPZpzUUN3ME2xO{4zODJ6IN88US=>	MlP2V2FPT0WU
T84	NIXnZXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2K1TWlEPTB;MUiuPFY6PSEQvF2=	NXnKPXdIW0GQR1XS
KU-19-19	NGLKdolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTF6Lkm2NFgh\|ryP	M2fvPXNCVkeHUh?=
BALL-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HucWlEPTB;MUmuN\|M6QSEQvF2=	M{XpOHNCVkeHUh?=
Calu-6	Mn[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\KcXB1UUN3ME2xPU41QTJizszN	MYXTRW5ITVJ?
EGI-1	NV;z[pBiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvRe\|ZKSzVyPUG5MlU6QCEQvF2=	MX;TRW5ITVJ?
MFH-ino	M4jIfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\WVWlEPTB;MUmuO\|Q2PCEQvF2=	MkHsV2FPT0WU
GB-1	NYfBeoVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjHdpBFUUN3ME2yNE4{PTN3IN88US=>	MnXVV2FPT0WU
NCI-H1693	M1u3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofTTWM2OD1{MD62OVA2KM7:TR?=	NWDUUnNSW0GQR1XS
SW1116	MnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWriUmtLUUN3ME2yNE46OzZ{IN88US=>	M13QZXNCVkeHUh?=
H-EMC-SS	M2XqbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXKTWM2OD1{Mj6wOFUh\|ryP	NYS3cpNzW0GQR1XS
D-502MG	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfkOoNKSzVyPUKyMlgzPjFizszN	NWLFRVhQW0GQR1XS
IA-LM	MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDQTWM2OD1{Mz6yOFk{KM7:TR?=	NVP6PZVDW0GQR1XS
SW1463	NWHaWndjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTaZ2ZZUUN3ME2yN{44QSEQvF2=	NGnYS2FUSU6JRWK=
JAR	M3i2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTJ2LkOyPVMh\|ryP	NHXifFhUSU6JRWK=
HT	NInFfJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\BV2lEPTB;MkSuOFc2OyEQvF2=	M1vacXNCVkeHUh?=
LCLC-103H	M4PpZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTJ2Lki0OFkh\|ryP	NV2zelFLW0GQR1XS
SNU-449	NFH1d3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rnbmlEPTB;MkSuPFc1OSEQvF2=	Mon4V2FPT0WU
KE-37	MoPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzsZpg3UUN3ME2yOU4xQTJ6IN88US=>	NW\Kcm5{W0GQR1XS
NCI-H1623	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDtTWM2OD1{Nz6xN\|A{KM7:TR?=	M1vFcHNCVkeHUh?=
MOLT-13	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXyTWM2OD1{Nz6zOVE3KM7:TR?=	NEe2[mpUSU6JRWK=
COLO-741	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTNzLkOzN\|Mh\|ryP	MV;TRW5ITVJ?
NB6	M{nuNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVy1U3ZpUUN3ME2zNk4zQDd4IN88US=>	NWPncoxrW0GQR1XS
MOLT-16	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUS1XmtuUUN3ME2zN{4xODV3IN88US=>	NYOyWXB3W0GQR1XS
IST-MES1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn2xTWM2OD1\|ND6wOVQyKM7:TR?=	NHnZNHhUSU6JRWK=
A4-Fuk	M3;vT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLLTWM2OD1\|NT6wOlYh\|ryP	Mk\IV2FPT0WU
CAL-85-1	NHjzdFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3P2RmlEPTB;M{WuNlgyPyEQvF2=	M2TXeXNCVkeHUh?=
CCRF-CEM	M4HQXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\2TnNKSzVyPUO3MlE2OzZizszN	MV\TRW5ITVJ?
HAL-01	M3jGTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDQNHZKSzVyPUO4MlQ5QDlizszN	NFyzSnFUSU6JRWK=
HEL	NFqyWYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnmO2pkUUN3ME20N{4{PDB7IN88US=>	M{DRcnNCVkeHUh?=
EW-1	NFfPbGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWXQN4s5UUN3ME20N{41PzZ6IN88US=>	MmnGV2FPT0WU
MDA-MB-231	MoPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEi4U5VKSzVyPUS1MlEyQTlizszN	MYfTRW5ITVJ?
ABC-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzle2NKSzVyPUS2Mlg2OzhizszN	NHr0b5JUSU6JRWK=
NCI-H446	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4j6bGlEPTB;NEiuOVA2QCEQvF2=	NIL3ZnJUSU6JRWK=
MHH-PREB-1	MnnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjGTWM2OD12OT62NFA4KM7:TR?=	MXHTRW5ITVJ?
DOHH-2	NXPHeI5OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTPTWM2OD12OT62OlU3KM7:TR?=	M{DJRnNCVkeHUh?=
GCT	NVvRb3JHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnL4TWM2OD12OT62PVc3KM7:TR?=	MVTTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	α-Synuclein / HSP90 / HSP70 / HSP32 / αB-Crystallin; PubMed: 20090920 PLoS One Immunoblot analysis of heat shock protein induction. Cells were treated with 17-AAG (1–200 nM, 24 h), or subjected to heat shock (HS: 44°C, 30 min, 24 h recovery) or to MG-132 (MG: 1 µM, 24 h). Cell lysates were prepared and immunoblot analysis was carried out with antibodies against the individual proteins as indicated on the right. Co, untreated control. EGFR / PDGFR / AKT / MAPK / c-RAS; PubMed: 18682579 Neuro Oncol 17-AAG promotes the degradation of HSP90 client proteins that are involved in the pathology of glioblastoma multiforme (GBM). Glioma cell lines were treated with increasing concentrations of 17-AAG for 48 h, and protein lysates were run on Western blots. HSP90 client proteins known to be involved in gliomagenesis showed degradation while nonclient proteins remained unaffected by 17-AAG treatment. pAKT / pMAPK / pRb; PubMed: 18682579 Neuro Oncol The phosphorylated states of signaling proteins involved in glioma growth are also affected by 17-AAG treatment. Cleaved PARP / Survivin; PubMed: 18827603 J Thorac Oncol Western analysis of expression levels of cleaved PARP and Survivin in MM cell lines. β-Actin served as loading control. LATS1 / p-LATS1 / YAP / CTGF; PubMed: 25712415 J Cell Mol Med Effects of 17-AAG on the expression of LATS1, p-LATS1, YAP and CTGF. The expression levels of YAP and CTGF proteins, indicated by Western blot assay, were down-regulated, while LATS1 was upregulated in a dose-dependent manner in 17-AAG treated groups compared to the untreated group.	20090920 18682579 18827603 25712415
Immunofluorescence	STAT3; PubMed: 27279418 Mol Med Rep Effects of 17-AAG on STAT3 expression of H446 cells. (A) Control group; (B) 3.125 mg/l; (C) 6.25 mg/l. 17-AAG, 17-allylamino-17-demethoxygel-danamycin; STAT3, signal transducer and activator of transcription 3; DAPI, 4′,6-diamidino-2-phenylindole. YAP / TAZ; PubMed: 25290150 PLoS One Reduction in cytoplasmic distribution accompanied by increased nuclear localization of YAP/TAZ was more apparent in cells treated with 45 nM 17-AAG (red channel for YAP/TAZ and blue channel for nucleus). Statistical comparisons were performed using one-way Kruskal-Wallis multiple comparison, ***p<0.001 compared with control (0 nM). β-catenin / E-cadherin; PubMed: 25290150 PLoS One Co-localization of β-catenin (Red) and E-cadherin (Green) was observed at the cell-cell junctions (white arrows) both in siCtrl and siCTGF cells after 17-AAG treatment. Scale bar is 20 µm.	27279418 25290150
Growth inhibition assay	Cell viability; PubMed: 18682579 Neuro Oncol 17-AAG inhibits the growth of human glioma cell lines. Human glioma cell lines and a nontumorigenic fibroblast cell line were treated with increasing concentrations of 17-AAG for 4 days, and the effect on cell growth was assessed by a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay. The 50% inhibitory concentration (IC50) of all glioma cell lines ranged from 0.05 to 0.5 μM 17-AAG, as compared to 1.5 μM for the nontumorigenic cells.	18682579

In vivo

17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. ^[1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse Hsp90 binding assays: Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl₂, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research:^[1]	- Collapse Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 5 days Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A₄₉₀) of wells not containing cells is subtracted. Percentage of viable cells = (A₄₉₀ of 17-AAG treated sample/A₄₉₀ untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number. (Only for Reference)
Animal Research:^[2]	- Collapse Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6 Formulation: Dissolved in DMSO, and diluted in egg phospholipids (EPL) vehicle Dosages: ~50 mg/kg Administration: Injection i.p. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (170.73 mM)
	Ethanol	5 mg/mL (8.53 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+corn oil For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Tanespimycin (17-AAG) SDF

Molecular Weight	585.69
Formula	C₃₁H₄₃N₃O₈
CAS No.	75747-14-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	CP127374,NSC-330507, KOS 953

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00103272	Terminated	Drug: tanespimycin\|Drug: bortezomib	Adult Acute Basophilic Leukemia\|Adult Acute Eosinophilic Leukemia\|Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult T-cell Leukemia/Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides/Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Waldenström Macroglobulinemia	National Cancer Institute (NCI)	April 2005	Phase 1
NCT00098488	Terminated	Drug: tanespimycin\|Biological: rituximab	B-cell Chronic Lymphocytic Leukemia\|Prolymphocytic Leukemia\|Refractory Chronic Lymphocytic Leukemia	National Cancer Institute (NCI)	April 2005	Phase 1
NCT00118248	Completed	Drug: tanespimycin	Recurrent Thyroid Cancer\|Stage IV Follicular Thyroid Cancer\|Stage IV Papillary Thyroid Cancer\|Thyroid Gland Medullary Carcinoma	National Cancer Institute (NCI)	December 2004	Phase 2
NCT00098423	Completed	Drug: tanespimycin\|Drug: cytarabine	Accelerated Phase Chronic Myelogenous Leukemia\|Adult Acute Basophilic Leukemia\|Adult Acute Eosinophilic Leukemia\|Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Blastic Phase Chronic Myelogenous Leukemia\|Chronic Myelomonocytic Leukemia\|de Novo Myelodysplastic Syndromes\|Previously Treated Myelodysplastic Syndromes\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Refractory Anemia With Excess Blasts in Transformation\|Relapsing Chronic Myelogenous Leukemia\|Secondary Acute Myeloid Leukemia\|Secondary Myelodysplastic Syndromes	National Cancer Institute (NCI)	November 2004	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?
Answer:
17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Selective HSP90 Inhibitor

NVP-BEP800 : HSP90β-selective, IC50=58 nM.
Most Potent HSP90 Inhibitor

KW-2478 : HSP90, IC50=3.8 nM.
HSP90 Inhibitor in Clinical Trial

17-DMAG (Alvespimycin) HCl : Phase II for Kidney Cancer.
Newest HSP90 Inhibitor

XL888 : ATP-competitive inhibitor of HSP90 with IC50 of 24 nM.

Related HSP (e.g. HSP90) Products

PU-H71 ^New

PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90.
Luminespib (AUY-922, NVP-AUY922)

Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Phase 2.
Ganetespib (STA-9090)

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin

Geldanamycin is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.
HSP990 (NVP-HSP990)

NVP-HSP990 (HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Elesclomol (STA-4783)

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Tanespimycin (17-AAG)

Cited by 41 Publications

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Tanespimycin (17-AAG) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products

Choose Your Country or Region

By Signaling Pathways

By product type

Tanespimycin (17-AAG)

Cited by 41 Publications

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Tanespimycin (17-AAG) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)